Empagliflozin improves pressure-overload-induced cardiac hypertrophy by inhibiting the canonical Wnt/β-catenin signaling pathway

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Frontiers in Pharmacology

Topics

Biology

Internal Medicine

Medicine

Endocrinology

Cardiology

Show all topics

DOI

10.3389/fphar.2024.1499542

License

CC-BY